<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-22256" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Glargine Insulin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Cunningham</surname>
            <given-names>Abigail M.</given-names>
          </name>
          <aff>Campbell University School of Osteopathic Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Freeman</surname>
            <given-names>Andrew M.</given-names>
          </name>
          <aff>Southeastern Regional Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abigail Cunningham declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Andrew Freeman declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>12</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-22256.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Insulin glargine is a synthetic version of human insulin that is FDA-approved to treat adults and children with type 1 diabetes and adults with type 2 diabetes to improve and maintain glycemic control. Insulin glargine is a long-acting insulin injected once daily and provides a basal insulin level throughout the day. Regimens often combine it with rapid-acting insulin to obtain optimal glycemic control. The insulin should not be used to treat diabetic ketoacidosis, as short-acting insulin is preferred. This activity will cover the indications, mechanism of action, adverse effects, contraindications, monitoring, and toxicity of insulin glargine pertinent for healthcare professionals.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of insulin glargine.</p></list-item><list-item><p>Determine&#x000a0;the contraindications of insulin glargine.</p></list-item><list-item><p>Apply&#x000a0;the appropriate monitoring for insulin glargine.</p></list-item><list-item><p>Communicate&#x000a0;some interprofessional team strategies for improving care coordination and communication to advance treatment with insulin glargine and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22256&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22256">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-22256.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Insulin glargine is a synthetic version of human insulin that is FDA-approved to improve and maintain glycemic control in adults and children with type 1 diabetes and adults with type 2 diabetes. It is a long-acting insulin injected once daily that provides a basal insulin level throughout the day. Regimens often combine it with rapid-acting insulin to obtain&#x000a0;optimal glycemic control. The insulin should not be used to treat diabetic ketoacidosis, as short-acting insulin is preferred.&#x000a0;</p>
        <p>In type 1 diabetes, long-acting and short-acting insulins are often necessary at the onset of the disease. In this condition, the body lacks the ability to produce insulin from the pancreas due to autoimmune-mediated beta cell destruction, resulting in a rapid loss of regulation of blood glucose levels. Insulin glargine functions as basal glycemic control due to its 24-hour duration of action, while rapid-acting insulin works as coverage of elevated blood glucose and carbohydrate intake due to its&#x000a0;quick onset and short duration of action.&#x000a0;</p>
        <p>In adults with type 2 diabetes, insulin glargine, or another long-acting insulin, should be initiated for glycemic control after 2 or 3 oral antidiabetic medications have failed to attain glycemic control or in patients with a hemoglobin A1c value higher than 9% experiencing symptoms. Insulin glargine may be used alone in&#x000a0;individual patients or with rapid-acting insulin or oral medication(s) for diabetes management.&#x000a0;Insulin glargine does not have approval for children with type 2 diabetes.<xref ref-type="bibr" rid="article-22256.r1">[1]</xref>&#x000a0;&#x000a0;</p>
        <p>Insulin glargine is not FDA-approved in pregnancy, although studies have not shown contraindications to its use or adverse fetal outcomes. It is considered&#x000a0;a&#x000a0;first-line treatment for gestational diabetes after lifestyle modifications have proven insufficient.<xref ref-type="bibr" rid="article-22256.r2">[2]</xref><xref ref-type="bibr" rid="article-22256.r3">[3]</xref></p>
      </sec>
      <sec id="article-22256.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Insulin glargine is a recombinant human insulin analog that binds to receptors (IR). Insulin is necessary to regulate lipid, glucose, and energy homeostasis. It acts mainly on the skeletal muscle, adipose tissue, and liver. The IR is a tyrosine kinase receptor with&#x000a0;2 extracellular alpha domains and&#x000a0;2 intracellular catalytic beta domains. Upon insulin binding, a conformational change occurs to the beta catalytic domains&#x000a0;that activate the tyrosine kinase domains, causing them to auto-phosphorylate the beta subunits. Once activated, the beta subunits can bind docking proteins,&#x000a0;which leads to the activation of phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3k) and an intracellular signaling cascade, eventually activating&#x000a0;protein kinase B (also known as Akt). Akt regulates the activity of the glucose transporter type 4 (GLUT4) receptor, protein kinase C (PKC), and the mitogen-activated protein&#x000a0;kinase (MAPK or MAP kinase) pathway.<xref ref-type="bibr" rid="article-22256.r4">[4]</xref></p>
        <p>Insulin glargine has an onset of action of 1.5 to 2 hours. It has a long duration of action of up to 24 hours due to modifications of amino acids, including Asn to Gly at position 21 of the A chain and the addition of&#x000a0;2 Arg residues and positions 31 and 32 of the B chain. This arrangement allows the insulin to remain&#x000a0;soluble at a pH of 4.0, the pH of the solution in which it is administered, and then become insoluble at physiologic pH. Once insulin glargine is injected into the body and introduced to the higher pH, the insoluble precipitate that forms slowly releases soluble protein over 24 hours.<xref ref-type="bibr" rid="article-22256.r5">[5]</xref></p>
      </sec>
      <sec id="article-22256.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Insulin glargine comes either in 100 ml vials or dosing pens containing 3 ml cartridges of medication and is administered via subcutaneous injection only. The drug is available at a concentration of 100 units per ml. Its administration includes a&#x000a0;diluent with a pH of 4.0 to maintain the solubility of the drug before use. The medication is administered once daily at the same time of day by the patient. Decisions of when to administer insulin glargine depend on the patient's schedule and the effect of insulin on the patient's&#x000a0;blood glucose levels. Patients should rotate injection sites to avoid lipodystrophy; these include the top of the thighs, back of the upper arms, buttocks, or abdomen.&#x000a0;</p>
        <p>The estimated starting dose of insulin therapy&#x000a0;is usually&#x000a0;0.4 to 0.5 units/kg per day of total insulin. However, differing amounts might be necessary for patients undergoing puberty or those with obesity. The consensus regarding basal insulin dosing is that it should make up 50% of the total daily insulin requirement. However, it is worth noting that recent studies have suggested that a basal dose closer to 40% of total daily insulin may result in more optimal glycemic control.<xref ref-type="bibr" rid="article-22256.r6">[6]</xref></p>
      </sec>
      <sec id="article-22256.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The most common adverse effect of insulin glargine is hypoglycemia. Special attention is necessary for insulin usage in fasting patients who have recently changed their diets or have had recent activity changes, such as beginning a workout program. Hypoglycemia characteristically demonstrates autonomic symptoms, including diaphoresis, nausea, palpitations, tremors, anxiety, lethargy, and decreased concentration, among others. With severe hypoglycemia, unconsciousness, seizures, coma, and death may occur. Adverse effects may also include allergic reactions to the diluent, site injection reactions or infection, and lipodystrophy at the injection site. Insulin glargine may also cause pain upon injection at the site due to the acidity of the diluent.<xref ref-type="bibr" rid="article-22256.r7">[7]</xref></p>
        <p>It is also essential to be aware of medications administered concurrently with insulin glargine. Certain medications can increase the risk of hypoglycemia when given&#x000a0;concomitantly with&#x000a0;insulin. Certain medications may also diminish the effectiveness of insulin glargine, causing hyperglycemia or masking symptoms of hypoglycemia. The risk of hypoglycemia may increase with the coadministration of antidiabetic drugs, other insulins, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, propoxyphene, salicylates, sulfonamide antibiotics, and somatostatin analogs. The effectiveness of insulin glargine may diminish when administered with atypical antipsychotics, corticosteroids, danazol, diuretics, estrogens, isoniazid, niacin, phenothiazines protease inhibitors, somatotropin, sympathomimetic agents, and thyroid hormone replacements.<xref ref-type="bibr" rid="article-22256.r8">[8]</xref></p>
        <p>Another concern regarding drug interactions includes the possibility of medications such as beta-blockers, clonidine, guanethidine, and reserpine masking symptoms of hypoglycemia. Lastly, thiazolidinediones have an increased risk of causing dose-related fluid retention&#x000a0;when administered with insulin.</p>
      </sec>
      <sec id="article-22256.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Insulin glargine is contraindicated in patients with a documented hypersensitivity to the drug or&#x000a0;1 of its components. It also should not be administered during a hypoglycemic episode. However, patients can restart the medication once the episode has resolved. Caution is advisable in infection, hypokalemia, kidney dysfunction, and liver disease.<xref ref-type="bibr" rid="article-22256.r9">[9]</xref></p>
        <p>Insulin glargine is considered&#x000a0;safe during pregnancy, and there&#x000a0;are no known risks of infant harm if using the medication during lactation. However, the FDA lists insulin glargine as category C in pregnancy, stating that the patient should only use it if the benefits outweigh the risks.<xref ref-type="bibr" rid="article-22256.r10">[10]</xref><xref ref-type="bibr" rid="article-22256.r2">[2]</xref><xref ref-type="bibr" rid="article-22256.r10">[10]</xref><xref ref-type="bibr" rid="article-22256.r2">[2]</xref></p>
      </sec>
      <sec id="article-22256.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>There is no specific safe range for insulin glargine as the dose is adjusted individually and depends on factors specific to the individual, including responsiveness to the insulin, diet, and daily routine. Other contributing factors&#x000a0;that merit consideration during dosing include the type of diabetes, body weight, compliance, and rate of medication elimination. Safety issues that can arise include confusing insulin glargine with another insulin the patient takes concurrently. If an individual takes an inappropriate insulin dose, they are at high risk of suffering severe hypoglycemia.</p>
        <p>The effects of insulin glargine are monitored on an outpatient basis utilizing a glucometer or continuous glucose monitor to follow blood glucose trends. The dosing of insulin depends on those findings. Continuous glucose monitors are becoming a more popular means to monitor blood glucose levels and&#x000a0;the efficacy of an insulin regimen.<xref ref-type="bibr" rid="article-22256.r11">[11]</xref></p>
      </sec>
      <sec id="article-22256.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Overdose of insulin glargine leads to hypoglycemia, which can be severe and persistent due to the long-acting nature of this insulin. In the case of mild hypoglycemia, carbohydrate intake is typically sufficient to restore euglycemia. The patient should ingest 15 grams of carbohydrates, wait 15 minutes, and recheck their blood glucose level. If it remains hypoglycemic, the procedure is repeated. In the case of severe hypoglycemia or if there is a reason that oral intake is not possible, then injectable glucagon is an option. Another option typically reserved for severe hypoglycemia in the hospital or EMS setting is intravenous dextrose. From published reports, dextrose infusion alone was sufficient to correct hypoglycemia. The long-acting nature of the insulin must also merit consideration; dextrose infusions may need to be repeated&#x000a0;beyond the predicted 24-hour lifetime of the medication.<xref ref-type="bibr" rid="article-22256.r12">[12]</xref><xref ref-type="bibr" rid="article-22256.r13">[13]</xref><xref ref-type="bibr" rid="article-22256.r14">[14]</xref></p>
      </sec>
      <sec id="article-22256.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The increasing rates of type 2 diabetes and the relative paucity of endocrinologists&#x000a0;mean that initiating glucose control in uncomplicated type 2 diabetes should be part of the routine practice of&#x000a0;interprofessional healthcare teams. Ideally, these teams would comprise clinicians (MDs, DOs, NPs, PAs), practice nurses,&#x000a0;pharmacists, and certified diabetes educators. Some obstacles to implementing such care within a primary interprofessional team include ambiguity of roles, uncertainty of competency, and poor communication. For example, there is some&#x000a0;ambiguity in the role of the primary care versus specialist clinician in initiating insulin and determining which patients do or do not&#x000a0;meet the criteria of 'complicated.' Furthermore, there are misunderstandings regarding the ability to administer, educate, and adjust insulin between clinicians, practice nurses, and diabetes nurse educators.</p>
        <p>Finally,&#x000a0; poor communication between professional categories can lead to inadequate care, such that physicians communicate better with other physicians than with practice nurses,&#x000a0;etc. Overcoming the abovementioned obstacles can lead to better patient outcomes and improved safety. This study has some limitations due to its use of a convenience sample of providers. Also, the study focused on provider factors that affect patient outcomes and did not consider any factors that may have impacted patient outcomes.<xref ref-type="bibr" rid="article-22256.r15">[15]</xref>&#x000a0;However, all of these factors point towards interprofessional team management of diabetes in general and the use of insulin glargine specifically, driving better patient outcomes.</p>
      </sec>
      <sec id="article-22256.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22256&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22256">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/22256/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=22256">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-22256.s11">
        <title>References</title>
        <ref id="article-22256.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghosal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sinha</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Majumder</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Das</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Ghoshdastidar</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Maji</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Goyal</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mukherjee</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Gangopadhyay</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>John</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chatterjee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jaggi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ray</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Majumdar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Consensus on "Basal insulin in the management of Type 2 Diabetes: Which, When and How?".</article-title>
            <source>J Assoc Physicians India</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>65</volume>
            <issue>7</issue>
            <fpage>51</fpage>
            <page-range>51-62</page-range>
            <pub-id pub-id-type="pmid">28792170</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22256.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Finneran</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Landon</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>Oral Agents for the Treatment of Gestational Diabetes.</article-title>
            <source>Curr Diab Rep</source>
            <year>2018</year>
            <month>Sep</month>
            <day>28</day>
            <volume>18</volume>
            <issue>11</issue>
            <fpage>119</fpage>
            <pub-id pub-id-type="pmid">30267230</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22256.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alfadhli</surname>
                <given-names>EM</given-names>
              </name>
            </person-group>
            <article-title>Gestational diabetes mellitus.</article-title>
            <source>Saudi Med J</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>36</volume>
            <issue>4</issue>
            <fpage>399</fpage>
            <page-range>399-406</page-range>
            <pub-id pub-id-type="pmid">25828275</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22256.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boucher</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kleinridders</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kahn</surname>
                <given-names>CR</given-names>
              </name>
            </person-group>
            <article-title>Insulin receptor signaling in normal and insulin-resistant states.</article-title>
            <source>Cold Spring Harb Perspect Biol</source>
            <year>2014</year>
            <month>Jan</month>
            <day>01</day>
            <volume>6</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">24384568</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22256.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Candido</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wyne</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Romoli</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus.</article-title>
            <source>Diabetes Ther</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>927</fpage>
            <page-range>927-949</page-range>
            <pub-id pub-id-type="pmid">29654514</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22256.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>King</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Kuroda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Matsuhisa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hobbs</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>A Review of Insulin-Dosing Formulas for Continuous Subcutaneous Insulin Infusion (CSII) for Adults with Type 1 Diabetes.</article-title>
            <source>Curr Diab Rep</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>16</volume>
            <issue>9</issue>
            <fpage>83</fpage>
            <pub-id pub-id-type="pmid">27457238</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22256.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hope</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Shields</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Hattersley</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Hamilton</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Are we missing hypoglycaemia? Elderly patients with insulin-treated diabetes present to primary care frequently with non-specific symptoms associated with hypoglycaemia.</article-title>
            <source>Prim Care Diabetes</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>139</fpage>
            <page-range>139-146</page-range>
            <pub-id pub-id-type="pmid">28918198</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22256.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pratley</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Emerson</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Franek</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gilbert</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Marso</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>McGuire</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Pieber</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Zinman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Mark</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Moses</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Buse</surname>
                <given-names>JB</given-names>
              </name>
              <collab>DEVOTE Study Group</collab>
            </person-group>
            <article-title>Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7).</article-title>
            <source>Diabetes Obes Metab</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>21</volume>
            <issue>7</issue>
            <fpage>1625</fpage>
            <page-range>1625-1633</page-range>
            <pub-id pub-id-type="pmid">30850995</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22256.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vargas-Uricoechea</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Aschner</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Comparative efficacy and safety of basal insulins: A review.</article-title>
            <source>Diabetes Metab Syndr</source>
            <year>2021</year>
            <season>Nov-Dec</season>
            <volume>15</volume>
            <issue>6</issue>
            <fpage>102318</fpage>
            <pub-id pub-id-type="pmid">34695771</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22256.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jethwani</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Saboo</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jethwani</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chawla</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Maheshwari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jaggi</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Use of insulin glargine during pregnancy: A review.</article-title>
            <source>Diabetes Metab Syndr</source>
            <year>2021</year>
            <season>Jan-Feb</season>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>379</fpage>
            <page-range>379-384</page-range>
            <pub-id pub-id-type="pmid">33540243</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22256.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhai</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jing</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Su</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Evaluating Glycemic Control During Basalin or Lantus Administration in Adults With Controlled Type 2 Diabetes Mellitus Using Continuous Glucose Monitoring.</article-title>
            <source>Front Endocrinol (Lausanne)</source>
            <year>2021</year>
            <volume>12</volume>
            <fpage>754820</fpage>
            <pub-id pub-id-type="pmid">34917025</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22256.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karatas</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sahin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Karatas</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Karsli</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Emre</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kivrakoglu</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>The highest (3600 IU) reported overdose of insulin glargine ever and management.</article-title>
            <source>Indian J Crit Care Med</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>19</volume>
            <issue>12</issue>
            <fpage>750</fpage>
            <page-range>750-1</page-range>
            <pub-id pub-id-type="pmid">26813353</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22256.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eldred</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Mustafa</surname>
                <given-names>OG</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Whitelaw</surname>
                <given-names>BC</given-names>
              </name>
            </person-group>
            <article-title>Problem based review: the patient who has taken an overdose of long-acting insulin analogue.</article-title>
            <source>Acute Med</source>
            <year>2013</year>
            <volume>12</volume>
            <issue>3</issue>
            <fpage>167</fpage>
            <page-range>167-72</page-range>
            <pub-id pub-id-type="pmid">24098877</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22256.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Do&#x0011f;an</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Onur</surname>
                <given-names>OE</given-names>
              </name>
              <name>
                <surname>Alt&#x00131;nok</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>G&#x000f6;neysel</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Insulin glargine overdose.</article-title>
            <source>J Pharmacol Pharmacother</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>3</volume>
            <issue>4</issue>
            <fpage>333</fpage>
            <page-range>333-5</page-range>
            <pub-id pub-id-type="pmid">23326108</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22256.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Manski-Nankervis</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Furler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Blackberry</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>O'Neal</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Patterson</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Roles and relationships between health professionals involved in insulin initiation for people with type 2 diabetes in the general practice setting: a qualitative study drawing on relational coordination theory.</article-title>
            <source>BMC Fam Pract</source>
            <year>2014</year>
            <month>Jan</month>
            <day>31</day>
            <volume>15</volume>
            <fpage>20</fpage>
            <pub-id pub-id-type="pmid">24479762</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
